Article information
Full text is only aviable in PDF
REFERENCES
[1]
GL Armstrong, LA Conn, RW Pinner.
Trends in infectious disease mortality in the United States during the 20th century.
JAMA, 281 (1999), pp. 61-66
[2]
MJ Fine, MA Smith, CA Carson, et al.
Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis.
JAMA, 275 (1996), pp. 134-141
[3]
S Ewig, M Ruiz, A Torres, et al.
Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae..
Am J Respir Crit Care Med, 159 (1999), pp. 1835-1842
[4]
J Aspa, O Rajas, F Rodríguez de Castro, et al.
Drug-resistant pneumococcal pneumonia: clinical relevance and related factors.
Clin Infect Dis, 38 (2004), pp. 787-798
[5]
MJ Fine, TE Auble, DM Yealy, et al.
A prediction rule to identify low-risk patients with community-acquired pneumonia.
N Engl J Med, 336 (1997), pp. 243-250
[6]
WS Lim, MM van der Eerden, R Laing, et al.
Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study.
Thorax, 58 (2003), pp. 377-382
[7]
R Menéndez, A Torres, R Zalacain, et al.
Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome.
Thorax, 59 (2004), pp. 960-965
[8]
T Kuru, JP Lynch III.
Nonresolving or slowly resolving pneumonia.
Clin Chest Med, 20 (1999), pp. 623-651
[9]
SH Kirtland, RH Winterbauer.
Slowly resolving, chronic, and recurrent pneumonia.
Clin Chest Med, 12 (1991), pp. 303-318
[10]
SH Feinsilver, AM Fein, MS Niederman, DE Schultz, DH Faegenburg.
Utility of fiberoptic bronchoscopy in nonresolving pneumonia.
Chest, 98 (1990), pp. 1322-1326
[11]
AM Fein, SH Feinsilver, MS Niederman.
Nonresolving and slowly resolving pneumonia. Diagnosis and management in the elderly patient.
Clin Chest Med, 14 (1993), pp. 555-569
[12]
P Montravers, JY Fagon, J Chastre, et al.
Follow-up protected specimen brushes to assess treatment in nosocomial pneumonia.
Am Rev Respir Dis, 147 (1993), pp. 38-44
[13]
F Arancibia, S Ewig, JA Martínez, et al.
Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications.
Am J Respir Crit Care Med, 162 (2000), pp. 154-160
[14]
B Rosón, J Carratalá, N Fernández-Sabe, F Tubau, F Manresa, F Gudiol.
Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia.
Arch Intern Med, 164 (2004), pp. 502-508
[15]
R Menéndez, D Ferrando, JM Vallés, J Vallterra.
Influence of deviation from guidelines on the outcome of community-acquired pneumonia.
Chest, 122 (2002), pp. 612-617
[16]
MJ Bonten, AH Froon, CA Gaillard, et al.
The systemic inflammatory response in the development of ventilator-associated pneumonia.
Am J Respir Crit Care Med, 156 (1997), pp. 1105-1113
[17]
S Nelson.
Novel nonantibiotic therapies for pneumonia: cytokines and host defense.
Chest, 119 (2001), pp. 419-425
[18]
SJ Skerrett, DR Park.
Anti-inflammatory treatment of acute and chronic pneumonia.
Semin Respir Infect, 16 (2001), pp. 76-84
[19]
C Monton, A Torres, M el-Ebiary, X Filella, A Xaubet, JP de la Bellacasa.
Cytokine expression in severe pneumonia: a bronchoalveolar lavage study.
Crit Care Med, 27 (1999), pp. 1745-1753
[20]
M Ioanas, R Ferrer, M Ferrer, et al.
Causes and predictors of treatment failure in patients with ICU-acquired pneumonia.
Eur Respir J, 20 (2002), pp. 16
[21]
GW Waterer, MW Quasney, RM Cantor, RG Wunderink.
Septic shock and respiratory failure in community-acquired pneumonia have different TNF polymorphism associations.
Am J Respir Crit Care Med, 163 (2001), pp. 1599-1604
[22]
CE Luyt, V Guerin, A Combes, et al.
Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia.
Am J Respir Crit Care Med, 171 (2005), pp. 48-53
[23]
C Monton, S Ewig, A Torres, et al.
Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study.
Eur Respir J, 14 (1999), pp. 218-220
[24]
M Confalonieri, R Urbino, A Potena, et al.
Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study.
Am J Respir Crit Care Med, 19 (2004), pp. 19
[25]
GW Amsden.
Anti-inflammatory effects of macrolides–an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?.
J Antimicrob Chemother, 55 (2005), pp. 10-21
Copyright © 2005. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
